Fol. Biol. 2015, 61, 147-155
https://doi.org/10.14712/fb2015061040147
Benfluron Induces Cell Cycle Arrest, Apoptosis and Activation of p53 Pathway in MOLT-4 Leukemic Cells
References
1. 2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429.
< , J., Lukas, J. (https://doi.org/10.1016/S1535-6108(03)00110-7>
2. 2013) The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol. Cancer Ther. 12, 878-889.
< , Y., Chen, S., Kmieciak, M., Zhou, L., Lin, H., Pei, X.Y., Grant, S. (https://doi.org/10.1158/1535-7163.MCT-12-0902>
3. 2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 53, 153-159.
< , K. M. (https://doi.org/10.1007/s00262-003-0474-8>
4. 1987) The study of cytotoxic effect of benflurone. Neoplasma 27, 2.
, K., Jantová, S., Forgács, A., Perényl, T., Lukáčová, D. (
5. 1988) The mechanism of cytolytic and cytostatic activity of benfluron. Neoplasma 35, 177-184.
, K., Lukácová, D., Kozánková, J., Dzurba, A., Ziegelhöffer, A., Jantová, S. (
6. 1993) Expression of disodium cromoglygate ‘protective’ effects observed during V79 cell proliferation. Chem. Biol. Interact. 89, 103-113.
< , K., Vlcková, A., Lukácová, D. (https://doi.org/10.1016/0009-2797(93)90002-G>
7. 2001) Detection of drug-induced, superoxide-mediated cell damage and its prevention by antioxidants. Free Radic. Biol. Med. 30, 650-664.
< , K., Sovcíková, A., Seemannová, Z., Syrová, D., Busányová, K., Drobná, Z., Ferencík, M. (https://doi.org/10.1016/S0891-5849(00)00508-6>
8. 1992) Cytostatic activity of benzo(c)fluorene derivatives under in vitro conditions. Biologia 47, 725-736.
, S., Horáková, K., Uhrik, B., Novotova, M., Krepelka, J. (
9. 2001) The role of caspase-8 in resistance to cancer chemotherapy. Drug Resist. Updat. 4, 293-296.
< , P. K., Mahidhara, R., Seol, D. W. (https://doi.org/10.1054/drup.2001.0223>
10. 2012) ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation. PLoS One 7, e50281.
< , R. H., Greer, P. M., Cao, P. T., Cowan, K. H., Yan, Y. (https://doi.org/10.1371/journal.pone.0050281>
11. 2009) The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758.
< , A. J., Oren, M. (https://doi.org/10.1038/nrc2723>
12. 2008) Targeting cell death in tumors by activating caspases. Curr. Cancer Drug Targets 8, 98-109.
, S. H., Clark, A. C. (
13. 1989) Primary screening and inhibition of macromolecular biosynthesis by benfluron metabolites in vitro. Neoplasma 36, 91-101.
, M., Krepelka, J., Mĕlka, M., Vajdová, D. (
14. 1981) Antileukemic effects of 5-(2-dimethylaminoethoxy)-7-oxo-7H-benzo(c)fluorene, substance VUFB 13 468, on L1210 and La leukemia. Neoplasma 28, 715-720.
, V., Cernochová, S. (
15. 2011) The effect of ATM and ERK1/2 inhibition on mitoxantrone- induced cell death of leukaemic cells. Folia Biol (Praha) 57, 74-81.
, M., Havelek, R., Chmelařová, M., Cmielová, J., Muthná, D., Stoklasová, A., Zemánková, S., Rezáčová, M. (
16. 1987) Derivatives of benzo(c)fluorene. XXIV. Cytostatic effect of benfluron on human leukemic cells in vitro. Neoplasma 34, 45-54.
, J., Stöckbauer, P., Mĕlka, M., Koubek, K., Chudomel, V., Krepelka, J. (
17. 2002) ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710-12717.
< , D., Wu, D., Hirao, A., Lahti, J. M., Liu, L., Mazza, B., Kidd, V. J., Mak, T. W., Ingram, A. J. (https://doi.org/10.1074/jbc.M111598200>
18. 2009) γ-radiation- induced phosphorylation of p53 on serine 15 is dose-dependent in MOLT-4 leukaemia cells. Folia Biol (Praha). 55, 41-44.
, A., Záskodová, D., Zoelzer, F., Vávrová, J., Sinkorová, Z., Pejchal, J., Osterreicher, J., Rezácová, M. (
19. 2009) Blinded by the light: the growing complexity of p53. Cell 137, 413-431.
< , K. H., Prives, C. (https://doi.org/10.1016/j.cell.2009.04.037>
20. 2012) Autoregulatory mechanisms of phosphorylation of checkpoint kinase 1. Cancer Res. 72, 3786-3794.
< , J., Han, X., Zhang, Y. (https://doi.org/10.1158/0008-5472.CAN-12-0523>
21. 2007) Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26, 4689-4698.
< , Y., Black, C. P., Cowan, K. H. (https://doi.org/10.1038/sj.onc.1210268>